This study looks at how well two treatments work for liver cancer. One treatment is called TACE, which stands for *Transarterial Chemoembolization*. It delivers cancer-fighting medicine directly to the liver. The study compares TACE alone to TACE combined with two other treatments: immunotherapy (which helps the body's immune system fight cancer) and targeted therapy (which attacks cancer cells specifically).

Participants must be at least 18 years old and have liver cancer confirmed by certain tests. They should be in good general health and have a life expectancy of at least 8 weeks. The study also aims to find factors that affect how well these treatments work for different patients.

• The study is retrospective, meaning it looks at past patient data, so no visits or treatment are needed.
• Participants' data will help create a model to predict treatment outcomes.
• There is no direct risk or compensation for participants as it's based on existing records.